BioConference Live for the Life Science and Biotech Community

2-3 June 2010.
BioConference Live is an information break through and the first of its kind online-only conference for the life sciences and laboratory science community. This FREE event will feature live video keynote presentations from life science thought leaders where attendees can have their question answered by presenters in real time.

In addition, BioConference Live will feature a virtual exhibit hall, track sessions and case studies, and poster sessions where researchers present and discuss their latest work.

Topics Include:

  • Chemistry
  • Biotechnology
  • Cancer Research
  • Cellular Biology
  • Drug Discovery
  • Genetics
  • Immunology
  • Lab Automation
  • Medicine
  • Molecular Biology
  • Neuroscience
  • Venture Capital

Register and participate in over 50 Live keynote and track presentations from speakers such as Dr. David Wolf M.D. NASA Astronaut and Medical Doctor, Steven Burrill CEO of Burrill & Company, Kevin Hrusovsky M.B.A. CEO of Caliper Life Sciences, and Dr. Paul Schoemaker, Ph.D. Chairman and CEO Decision Strategies International, Inc., The Wharton School.

For further information and registration, please visit:
http://bioconferencelive.com

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Syntropy to unlock the value of scientific data in…

Merck, a leading science and technology company, and software company Palantir Technologies, today announced their intent to form a joint venture under the brand name Syn...